Literature DB >> 33585035

Expression and clinical significance of miR-1 and miR-133 in pre-diabetes.

Ghada Al-Kafaji1, Haifa Abdulla Al-Muhtaresh1, Abdel Halim Salem2.   

Abstract

Pre-diabetes represents an intermediate state of altered glucose metabolism between normal glucose levels and type 2 diabetes mellitus (T2D), and is considered a significant risk factor for the development of T2D and related complications. Early detection of pre-diabetes may allow for the use of timely and effective treatment strategies to prevent its progression. Circulating microRNAs (miRNAs/miRs) that reflect changes in diabetes-related tissues, including the pancreas, liver, skeletal and heart muscle, and adipose tissue are promising biomarkers of disease progression. In our previous study, it was demonstrated that the cardiac and skeletal muscle specific miR-1 and miR-133 are upregulated in the blood of patients with T2D and cardiovascular disease. Since both miRNAs have been shown to be implicated in insulin resistance, an important feature of pre-diabetes, we hypothesised that their expression may be increased prior to clinical diagnosis of T2D, and may thus serve as biomarkers for pre-diabetes. The expression levels of circulating miRNAs were evaluated by reverse transcription-quantitative PCR in whole blood samples from 55 subjects, including 28 pre-diabetes individuals with impaired fasting glucose (FG) and impaired glucose tolerance, and 27 healthy controls. The individuals with pre-diabetes exhibited significantly higher expression levels of miR-1 and miR-133 compared with the controls (P<0.05). Target prediction search revealed that both miR-1 and miR-133 target several pathways involved in the pathophysiology of diabetes. Pearson's correlation analysis revealed that the two miRNAs were positively correlated with blood glucose parameters, including FG, 2-h oral glucose tolerance test and glycated haemoglobin A1c levels, as well as with insulin resistance (P<0.05). Multivariate logistic regression analysis revealed that the two miRNAs were significantly and directly associated with pre-diabetes, and this association remained significant after adjustment for several confounding variables (P<0.05). Moreover, linear regression analysis showed that the Homeostatic Model Assessment-Insulin Resistance was the only significant predictor to be significantly associated with both miRNAs (P<0.05). In discriminating pre-diabetes individuals from healthy controls, the area under the curves (AUCs) of the receiver operating characteristic curves (ROCs) were 0.813 and 0.810 for miR-1 and miR-133 respectively (P<0.05). Despite the relatively small number of participants, the present study showed for the first time that circulating levels of miR-1 and miR-133 were increased in individuals with pre-diabetes, and they were associated with important features of pre-diabetes. Thus, they may serve as clinical biomarkers for the early-stages of T2D.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  biomarkers; circulating miRNAs; miR-1; miR-133; pre-diabetes

Year:  2021        PMID: 33585035      PMCID: PMC7873585          DOI: 10.3892/br.2021.1409

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  46 in total

Review 1.  microRNAs and muscle disorders.

Authors:  Jian-Fu Chen; Thomas E Callis; Da-Zhi Wang
Journal:  J Cell Sci       Date:  2009-01-01       Impact factor: 5.285

2.  Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI.

Authors:  Javier Gómez-Ambrosi; Camilo Silva; Juan C Galofré; Javier Escalada; Silvia Santos; María J Gil; Victor Valentí; Fernando Rotellar; Beatriz Ramírez; Javier Salvador; Gema Frühbeck
Journal:  Obesity (Silver Spring)       Date:  2011-03-10       Impact factor: 5.002

3.  Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions.

Authors:  Leonardo Elia; Riccardo Contu; Manuela Quintavalle; Francesca Varrone; Cristina Chimenti; Matteo Antonio Russo; Vincenzo Cimino; Laura De Marinis; Andrea Frustaci; Daniele Catalucci; Gianluigi Condorelli
Journal:  Circulation       Date:  2009-11-23       Impact factor: 29.690

4.  Prediabetes and lifestyle modification: time to prevent a preventable disease.

Authors:  Phillip Tuso
Journal:  Perm J       Date:  2014

Review 5.  Treating diabetes and prediabetes by focusing on obesity management.

Authors:  Lalita Khaodhiar; Sue Cummings; Caroline M Apovian
Journal:  Curr Diab Rep       Date:  2009-10       Impact factor: 4.810

Review 6.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

Review 7.  Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus.

Authors:  Katia Cristina Portero McLellan; Kathleen Wyne; Evangelina Trejo Villagomez; Willa A Hsueh
Journal:  Ther Clin Risk Manag       Date:  2014-03-20       Impact factor: 2.423

Review 8.  MicroRNAs in Cardiac Diseases.

Authors:  Robin M W Colpaert; Martina Calore
Journal:  Cells       Date:  2019-07-18       Impact factor: 6.600

Review 9.  Insulin-like growth factor-1 deficiency and metabolic syndrome.

Authors:  G A Aguirre; J Rodríguez De Ita; R G de la Garza; I Castilla-Cortazar
Journal:  J Transl Med       Date:  2016-01-06       Impact factor: 5.531

10.  Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus.

Authors:  Haifa Abdullah Al-Muhtaresh; Ghada Al-Kafaji
Journal:  J Clin Med       Date:  2018-01-26       Impact factor: 4.241

View more
  4 in total

1.  Association between metabolic disorders and seminal plasma miRNA levels: a pilot study.

Authors:  Sarah Saget; Laurent Kappeler; Valérie Grandjean; Patricia Leneuve; Isabelle Berthaut; Céline Faure; Sébastien Czernichow; Chrystèle Racine; Rachel Lévy; Charlotte Dupont
Journal:  Basic Clin Androl       Date:  2022-06-07

Review 2.  Regulating Polyamine Metabolism by miRNAs in Diabetic Cardiomyopathy.

Authors:  Tyler N Kambis; Hadassha M N Tofilau; Flobater I Gawargi; Surabhi Chandra; Paras K Mishra
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

Review 3.  A comprehensive overview on Micro RNA signature in type 2 diabetes Mellitus and its complications.

Authors:  Sanjukta Mishra; Jyotirmayee Bahinipati; RajLaxmi Sarangi; Soumya Ranjan Mohapatra; Swarnalata Das; Amaresh Mishra
Journal:  Indian J Clin Biochem       Date:  2022-09-05

4.  miR-378 affects metabolic disturbances in the mdx model of Duchenne muscular dystrophy.

Authors:  Paulina Podkalicka; Olga Mucha; Katarzyna Kaziród; Krzysztof Szade; Jacek Stępniewski; Liudmyla Ivanishchuk; Hirofumi Hirao; Ewelina Pośpiech; Alicja Józkowicz; Jerzy W Kupiec-Weglinski; Józef Dulak; Agnieszka Łoboda
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.